

Prescribing Clinical Network

Policy Statement	Once Daily Tadalafil
Policy Number	PCN 313-2018
Date of Issue	January - 2018
Review Date:	January - 2021 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
Recommendations:	
<p>The Prescribing Clinical Network does not recommend the use of once daily tadalafil</p> <p>Once daily tadalafil will be considered BLACK on the traffic light system prescribers should</p> <ul style="list-style-type: none"> ○ NOT initiate once daily tadalafil for any new patient AND ○ De-prescribe once daily tadalafil in all patients in line with NHS England guidance 	
Key Considerations:	
<ul style="list-style-type: none"> • NHS England guidance 'Items which should not routinely be prescribe in primary care: Guidance for CCGs' - https://www.england.nhs.uk/wp-content/uploads/2017/11/items-which-should-not-be-routinely-prescribed-in-pc-ccg-guidance.pdf • Benign Prostatic Hyperplasia: NICE terminated their technology appraisal (TA273) due to receiving no evidence from the manufacturer. In NICE CG97: Lower Urinary Tract Symptoms in Men. NICE state that there is not enough evidence to recommend phosphodiesterase inhibitors in routine clinical practice. • Erectile Dysfunction: PrescQIPP have reviewed the evidence for Tadalafil and although tadalafil is effective in treating erectile dysfunction, there is not enough evidence to routinely recommend once daily preparations in preference to "when required" preparations. https://www.prescqipp.info/tadalafil-drop-list/category/297-tadalafil-once-daily-drop-list 	
Date taken to Prescribing Clinical Network	10 th January 2018
Agreed by PCN members	22 nd January 2018

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG